{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.74","upperLimit":"3.88","value":"2.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions PFS using the product-limit method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV\n\npharmacological study: Correlative studies","id":"OG000","title":"Treatment (Ziv-aflibercept)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From start of treatment to time of progression, assessed up to 4 months","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}